Arcturus Therapeutics Holdings Inc
NASDAQ:ARCT

  • LAST PRICE
    17.0700
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    16.2500/ 5
  • Ask / Lots
    18.0000/ 1
  • Open / Previous Close
    --- / 17.0700
  • Day Range
    ---
  • 52 Week Range
    14.9301
    45.0000
  • Volume
    36

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
ARCT
Arcturus Therapeutics Holdings Inc
462.4M
-7.3x
---
SGMO
Sangamo Therapeutics Inc
408.1M
-2.8x
---
ADPT
Adaptive Biotechnologies Corp
644.9M
-3.3x
---
AKBA
Akebia Therapeutics Inc
397.1M
-8.2x
---
KMDA
Kamada Ltd
336.3M
18.9x
-22.48%
VNDA
Vanda Pharmaceuticals Inc
288.0M
-17.5x
-37.98%
As of 2024-11-22

Company Information

Arcturus Therapeutics Holdings Inc. is a global messenger RNA medicines and vaccine company. The Company is focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. In addition to its messenger RNA (mRNA) platform, its lipid nanoparticle (LNP) delivery system, LUNAR, has the potential to enable multiple nucleic acid medicines, and its self-amplifying mRNA technology (Self-Transcribing and Replicating RNA (STARR), technology) has the potential to provide longer-lasting RNA and sustained protein expression at lower dose level. It is leveraging its LUNAR platform and its nucleic acid technologies to develop and advance a pipeline of mRNA-based vaccines and therapeutics for infectious diseases and rare genetic disorders with significant unmet medical needs. Its COVID-19 vaccine candidate, which is based on its STARR technology platform is through Phase II clinical trials.

Contact Information

Headquarters
10628 Science Center Dr Ste 250SAN DIEGO, CA, United States 92121-1132
Phone
858-900-2660
Fax
302-636-5454

Executives

Independent Chairman of the Board
Peter Farrell
President, Chief Executive Officer, Director
Joseph Payne
Chief Financial Officer, Director
Andrew Sassine
Chief Operating Officer, Chief Scientific Officer
Padmanabh Chivukula
Chief Legal Officer
Lance Kurata

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$462.4M
Revenue (TTM)
$160.4M
Shares Outstanding
27.1M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
2.62
EPS
$-2.33
Book Value
$10.38
P/E Ratio
-7.3x
Price/Sales (TTM)
2.9
Price/Cash Flow (TTM)
---
Operating Margin
-50.22%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.